News | May 04, 2024
Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
2024 full-year revenue guidance raised by US$ 2 billion
Subscribe To Our Newsletter & Stay Updated
